Trial Condition(s):
Seborrheic Dermatitis on the Face
A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face
Bayer Identifier:
1401201
ClinicalTrials.gov Identifier:
EudraCT Number:
EU CT Number:
Not Available
Trial Purpose
This study is to determine whether a medication on the market for other indications is effective and safe in treating seborrheic dermatitis of the face.
Inclusion Criteria
- Stable or exacerbating seborrheic dermatitis in the facial area
Exclusion Criteria
- Psoriasis - Atopic dermatitis - Facial acne and rosacea - Dermatophytic skin infections - Parkinson's disease - Known immunosuppression; HIV infection - Any condition requiring continuous systemic or topical corticosteroid or antimycotic therapy - Continuous asthma inhalation treatment requiring > 800 mg corticosteroids - Any severe disease likely to interfere with the conduct or the planned termination of the study
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations SCIderm Scientific Research Hamburg, Germany, 20354 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Private Practice Buchholz, Germany, 21244 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Private Practice Blankenfelde-Mahlow, Germany, 15831 | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Private Practice Hamburg, Germany, 22049 | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
A Double-Blind, Randomized, Vehicle-Controlled, Six-Week Exploratory Multicenter Pilot Study of the Efficacy and Safety of Azelaic Acid (AzA) 15% Gel in the Topical Treatment of Mild to Moderate Seborrheic Dermatitis of the Face
Trial Type:
Interventional
Intervention Type:
Drug
Trial Purpose:
Treatment
Allocation:
Randomized
Blinding:
Double Blind
Assignment:
Parallel Assignment
Trial Arms:
2
Primary Outcome
- Sum Score of the symptoms of seborrheic dermatitis and the investigator's global assessment.Timeframe: Measurement of parameters during the course of treatment (six weeks)
Secondary Outcome
- Investigators' and patients' subjective assessment of improvement; frequency and intensity of single symptomsTimeframe: Measurement of parameters during the course of treatment (six weeks)
Additional Information
Copyright © Bayer
Powered by
